Searchable abstracts of presentations at key conferences in endocrinology

ea0016p764 | Thyroid | ECE2008

Clinical features and outcome of papillary thyroid cancers <2 cm: univariate and multivariate analyses

Perrino Michela , Vannucchi Guia , Vicentini Leonardo , Dazzi Davide , Peccoz Paolo Beck

An increasing prevalence of papillary thyroid carcinomas (PTC) of small size have been recorded in recent years. These tumors have a favorable outcome in most cases, and total thyroidectomy without radioiodine therapy is suggested for microcarcinomas (defined as ≤1 cm). The 6th edition of the TNM staging system for thyroid cancers includes in the T1 category tumors ≤2 cm, limited to the thyroid. Aim of the present study was to evaluate the clinical/pathological fea...

ea0032p824 | Pituitary–Basic (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Role of filamin-A in the regulation of SST2 receptor localization and signalling in tumoral GH-secreting cells

Giardino Elena , Peverelli Erika , Vitali Eleonora , Cambiaghi Valeria , Lania Andrea G , Peccoz Paolo Beck , Mantovani Giovanna , Spada Anna

Somatostatin (SS) binds to different SS receptors (SSTR1–5) and SS analogues are the first choice medical treatment of GH-secreting pituitary adenomas (GH-omas). A subset of patients is resistant to SS, although the mechanisms involved in SS resistance are not fully understood. Recent studies identified specific protein–protein interactions as determinant in the regulation of receptor anchoring and signalling. Filamin A (FLNA) is a widely expressed cytoskeleton prote...

ea0016p300 | Endocrine tumours | ECE2008

Proteomic profile of GH-secreting versus non-functioning pituitary tumors

Verpelli Chiara , Mantovani Giovanna , Locatelli Marco , Bello Lorenzo , Peccoz Paolo Beck , Spada Anna , Sala Claudio , Lania Andrea

GH-secreting and non-functioning pituitary tumors are clinically distinct, usually benign but potentially locally aggressive lesions originating from the replication of a single mutated pituitary cell. As for the underlying genetic and epigenetic alterations, also the patterns of activation of specific signaling pathways as well as the prognostic molecular factors leading to local invasiveness are, to date, largely unknown. In this study, we used two-dimensional electrophoresi...

ea0022oc3.4 | Pituitary | ECE2010

Influence of the d3-GH receptor polymorphism on the metabolic and biochemical phenotype of GH deficient adults at baseline and during short- and long-term rhGH replacement therapy

Giavoli Claudia , Ferrante Emanuele , Profka Eriselda , Olgiati Luca , Bergamaschi Silvia , Ronchi Cristina L , Verrua Elisa , Filopanti Marcello , Passeri Elena , Montefusco Laura , Lania Andrea G , Corbetta Sabrina , Arosio Maura , Ambrosi Bruno , Spada Anna , Peccoz Paolo Beck

A common polymorphic variant of the GH receptor (exon-3 deletion, d3GHR) has been linked with increased response to recombinant human GH (rhGH) in some, but not all, GH deficient (GHD) and non-GHD patients. Aim of this study was to investigate the impact of the GHR genotype on the phenotype of GHD adults and on the metabolic effect of short- and long-term rhGH therapy, with particular focus on glucose homeostasis (1 year: n=100 and 5 years: n=50). Effects of rhGH...